Telos Biotech parent, Cambrian Bio, to develop robust cell therapies for treating age-related diseases
Longevity Technology - 27-Jun-2023Novel recombinant protein to manufacture biologically fit cells by safely lengthening telomeres
James Peyer
Stem cell biologist out to build biotech companies focused on age-related diseases, CEO at Cambrian Biopharma
James Peyer, PhD is the Founder and CEO of a stealth-mode diversified pharmaceutical R&D holding company developing therapeutics targeting the biology of aging (‘geroscience’). The New York-based company builds, finances, and manages biotech companies. Dr. Peyer founded the company to translate laboratory breakthroughs in the extension of healthy lifespan into the clinic, predicting that the world is entering a revolution in biomedical research by targeting the root causes of aging and age-related disease.
Dr. Peyer has spoken on the topic of longevity biotech and investing for The Economist, TEDx, Longevity Leaders, ETH Zurich, and the Max Planck Institute on the Biology of Aging, to advance the mission of achieving widespread availability of longevity therapeutics this decade.
Before his current role, James was Founder and Managing Partner at Apollo Ventures, one of the major longevity-focused venture capital firms. Apollo has deployed over $20M and raised over $50M in the first three years of operations. He led investments in Cleara Biotech, Aeovian Pharmaceuticals, and Samsara Therapeutics and served on the Board and/or in executive roles for all three companies.
Visit website: https://leapsmag.com/author/james-peyer/
See also
Details last updated 24-Jan-2020
James Peyer News
Reason reports back from Age-Related Disease Therapeutics Summit 2023
Fight Aging! - 16-Jun-2023Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years
Vita Therapeutics raised $31m to develop treatment for genetic diseases and cancers
Business Wire - 12-Oct-2022Cell therapies aiming not only to correct the genetic defect but also repair and heal the muscle cells
A proactive step for next generation drug discovery by Cambrian Biopharma
Longevity Technology - 26-Oct-2021Novel business approach helps people to live longer with good health
Cambrian Biopharma raised $60 million in stealth mode
Longevity Technology - 09-Feb-2021New York-based biotech company with unique approaches to treat age-related diseases
Display all news
James Peyer is also referenced in the following:
Age-Related Disease Therapeutics Summit
31-May-2023 to 02-Jun-2023
Event about aging and aging related diseases organized by Hanson Wade
ARDD 2023 - 10th Aging Research & Drug Discovery Meeting
28-Aug-2023 to 01-Sep-2023
Event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen
Metabesity 2021
11-Oct-2021 to 14-Oct-2021
The Kitalys institute virtual conference targeting key questions that will impact the future of aging and extending healthspan
